I suspect there is a good % of valuation in SP just for the GVHD release. My thought is there will be a market revaluation of the technology upon the FDA approval. MSB needs to make hay whilst the sun shines given the overall industy pipeline for GVHD, heart and CLBP.
Safety is one of the key advantages here. But some big interests with huge scale are working in these areas so COGS pricing and reimbursement are still risks.
Ann: MSB Presents Commercial Plans at 2020 Biotech Showcase, page-46
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
0.105(9.09%) |
Mkt cap ! $1.438B | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.30 | $1.16 | $21.76M | 17.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 98636 | $1.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 600000 | 1 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.27 |
Change
0.105 ( 9.35 %) |
||||
| Open | High | Low | Volume | ||
| $1.17 | $1.30 | $1.16 | 2142493 | ||
| Last updated 15.59pm 28/05/2024 ? | |||||
| MSB (ASX) Chart |